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Abstract
Background and Objective We explored racial differences in
adherence to recommended clotting factor treatment regi-
mens, chronic pain, and quality of life (QoL) among adoles-
cents and young adults (AYAs) diagnosed with moderate or
severe hemophilia.
Methods A convenience sample of hemophilia patients aged
13–25 years completed an online cross-sectional survey in
2012. Chronic pain was measured using the revised Faces
Pain Scale (FPS-R) and dichotomized as high (FPS-R≥4) or
low (FPS-R<4). QoL was measured with the SF-36.
Results Of 80 AYA participants (79 male), most had severe
disease (91 %) and hemophilia A (91 %). Most were white
(76 %) and non-Hispanic (88 %). At the univariate level,
compared to whites, non-whites were more likely to have
produced an inhibitor against clotting factor treatment (74 vs
38 %, p<.01), less likely to have commercial health insurance
(16 vs 63 %, p<.001), more likely to report high levels of
chronic pain (FPS-R≥4) (63 vs 26 %, p<.01), and had lower
SF-36 physical composite summary (PCS) scores. Adjusted
logistic and quantile regression modeling, respectively, re-
vealed that non-whites were 5.31 (95 % CI 1.62, 17.4;
p<.01) times more likely to report high chronic pain and
had median PCS scores that were 26.0 (95 % CI 11.0, 40.9;
p<.01) points lower than whites.
Conclusions Targeted efforts to prevent and manage chronic
pain among non-white AYAs with moderate or severe hemo-
philia are necessary. After accounting for demographic and
clinical differences, there were no racial differences in adher-
ence to recommended clotting factor treatment regimens;
however, non-whites were more than five times more likely
to report high levels of chronic pain, which predicted worse
overall physical QoL, bodily pain, physical and social func-
tioning, and greater role limitations due to physical health.
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Background
Chronic pain is a known complication of persistent hemophil-
ia joint hemarthrosis. Despite being both a pervasive problem
among persons with hemophilia (PWH) and a well-known
predictor of general quality of life (QoL) [1–5], there are re-
markably few studies that have evaluated the prevalence and
management of chronic pain and the impact of chronic pain on
QoL among PWH. What few studies do exist have demon-
strated that chronic pain is suboptimally prevented [6] and
treated in PWH [2, 4, 7]. Specifically, previous research has
shown that more than one third of adults and nearly 1 in 10
children with hemophilia reported having chronic pain [2] and
that 39 % of adult PWH reported their pain was not well
managed [4].
Although this limited amount of research has provided
some insight into chronic pain among PWH, no studies have
evaluated whether racial differences exist in the development
and management of chronic pain among PWH. Studies
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describing racial differences in chronic pain related to hemo-
philia are warranted given that previous research in other dis-
ease areas has shown that racial minorities, particularly Afri-
can-Americans, report less pain tolerance/coping [8, 9], higher
overall levels of pain [8, 10–13], less control over pain [8, 10],
and more sequelae of chronic pain including worse QoL [9],
higher rates of depression [10, 12], more disability [13, 14],
and, in severe cases, the development of post-traumatic stress
disorder and other chronic pain syndromes [13]. These racial
differences have been shown to persist across all types of pain
[15] and across a variety of settings, including acute pain
managed in the emergency department, postoperative care,
childbirth, chronic non-cancer pain, arthritis pain, cancer-
related pain, and end-of-life care [16].
Adolescent and young adult (AYA) PWH are a subpopula-
tion for which data describing chronic pain, QoL, and racial
disparities are particularly lacking. AYAs are a unique popu-
lation of PWH who are often not only just starting to take
more responsibility for the management of their own disease
but also developing treatment habits that can carry over into
adult life [17]. Thus, developing proper pain management
strategies early on with AYA PWH is especially important.
Previous research, though not in PWH, has shown that youn-
ger individuals report more depressive symptoms and greater
pain intensity and are less successful at coping with pain [18].
Therefore, building strong pain management habits for AYA
PWH may be especially important in times during and just
before young adulthood, since it may be a time when coping
with pain is the most difficult. Our previous study discovered
that racial disparities in chronic pain may exist among AYA
with moderate or severe hemophilia and that a further, more
detailed analysis was warranted [6]. To that end, the primary
aim of this study was to evaluate racial/ethnic differences in
adherence to recommended clotting factor treatment regi-
mens, chronic pain, and QoL among AYAs with moderate or
severe hemophilia using data collected via a large cross-
sectional survey administered in 2012.
Methods
Study Population and Recruitment
Data describing self-reported adherence to recommended
treatment regimens, level of chronic pain, and QoL among
AYA persons with a bleeding disorder were obtained as part
of the larger Interrelationship between Management of Pain,
Adherence to Clotting factor Treatment, and Quality of Life
(IMPACT QoL) survey. As the name suggests, the IMPACT
QoL study had the primary goal of assessing the relationship
between validated measures of pain, clotting factor adherence,
and QoL among AYA PWH and AYAs with von Willebrand
disease (VWD). Data were collected via a one-time, cross-
sectional, online survey from a convenience sample of AYA
persons with a bleeding disorder. To be eligible to complete
the survey, participants had to i) be aged 13–25 years, ii) read,
write, and speak English, and iii) have hemophilia A, hemo-
philia B, or VWD. Recruitment occurred at major US hemo-
philia meetings (e.g., Inhibitor Summits and National Hemo-
philia Foundation meetings), US hemophilia treatment centers
(HTC), and through a Facebook™ (Facebook, Menlo Park,
CA, USA) page dedicated to the study from April through
December of 2012. All surveys were completed electronically
using SurveyMonkey™ (SurveyMonkey, Palo Alto, CA,
USA) and Apple iPads™ (Apple, Cupertino, CA, USA).
The study was approved by the Munson Medical Center (Tra-
verse City, MI) institutional review board prior to data collec-
tion. All data were de-identified prior to analysis.
The current study uses a patient subset (AYAs with mod-
erate or severe hemophilia) of the IMPACT QoL survey data
to analyze the relationship between race and three major fac-
tors related to the adequate management of hemophilia: i)
adherence to prescribed clotting factor treatment regimen, ii)
chronic pain, and iii) QoL. Participants with mild hemophilia
or VWD were excluded from this analysis because of small
sample size and to minimize heterogeneity in the assessment
of the primary hypothesis (i.e., those withmoderate and severe
hemophilia are at greatest risk of joint disease and chronic
pain resulting from hemarthroses).
Measurement
Race was self-reported as white, black or African-American,
Asian, American Indian or Alaskan Native, or mixed race.
Due to small sample size for non-white racial categories and
for purpose of analysis, race was dichotomized as white (only)
vs non-white. In addition to racial classification, we also col-
lected information about ethnicity (Hispanic vs non-Hispan-
ic). For purposes of analysis, racial and ethnic categories were
treated as two separate dichotomous variables; however, we
did conduct sensitivity analyses to determine if results were
similar for a combined racial/ethnic category (non-Hispanic
white vs non-white or Hispanic).
Adherence to recommended clotting factor treatment regi-
mens was assessed using the Validated Hemophilia Regimen
Treatment Adherence Scale (VERITAS)-Pro [19] for partici-
pants who reported treating their bleeding disorder prophylac-
tically. The VERITAS-PRN [20] was used to measure adher-
ence for participants who reported on-demand (i.e., episodic)
factor treatment. VERITAS scores range from 24 (most ad-
herent) to 120 (least adherent). As an experimental measure,
we also combined VERITAS-Pro and VERITAS-PRN re-
sponses into one category (VERITAS-combined) [21] to eval-
uate the relationship between adherence and QoL for both
prophylactic and on-demand AYA PWH simultaneously.
The cutoff for non-adherent prophylactic participants was a
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total VERITAS-Pro score ≥57 as previously established [19].
The cutoff for non-adherent on-demand patients has not been
previously described and was defined as those with
VERITAS-PRN in the highest quartile of all responses. This
value was chosen because the VERITAS-Pro cutoff was ap-
proximately the 75th percentile of all responses.
Chronic pain was measured using the revised Faces Pain
Scale (FPS-R). The FPS-R is a visual scale composed of six
faces illustrating an increasing level of pain intensity. Respon-
dents were asked to choose the face that best describes the
intensity of the chronic pain they experienced. In the IMPA
CT QoL survey, chronic pain was defined as Bpain that you
have every day or almost every day and that always or almost
always seems to be there even when you are not having a bleed
at that moment.^ FPS-R scores range from zero to 10 (in incre-
ments of two) with the faces representing the lowest and highest
levels of pain intensity coded as zero and 10, respectively. The
FPS-R is highly correlated with the visual analog scale (r=.93)
andwith the colored analog scale (r=.84), demonstrating strong
validity. Reliability and validity of the FPS-R have been
established for a broad age range, ranging from children as
young as 4 years old to adults [22]. For purpose of analysis,
chronic pain was dichotomized as high for those who reported
their pain as “4—moderate,” “6—severe,” “8—very severe,” or
B10—worst pain possible^ (i.e., FPS-R≥4) and low for B2—
mild pain,^ or B0—no pain^ (i.e., FPS-R<4). In addition, other,
non-validated pain-related measures were collected to assess
feelings of control over pain, use of prescribed pain medication,
and how well health care providers both managed and listened
to participants about their pain.
QoL was measured using the 36-Item Short Form Health
Survey (SF-36). The SF-36 is composed of 8multi-item scales
(35 items) assessing i) bodily pain (BP, 2 items), ii) physical
function (PF, 10 items), iii) role limitations due to physical
health problems (RP, 4 items), iv) general health (GH, 5
items), v) vitality (VT, 4 items), vi) social functioning (SF, 2
items), vii) role limitations due to emotional problems (RE, 3
items), and viii) emotional well-being/mental health (MH, 5
items) [23]. The 36th item, which asks about health change, is
not included in the scale or summary scores. Each SF-36 sub-
scale is calculated by standardizing the average of the partic-
ipant’s responses to the questions contained in the subscale, so
that each subscale has a final range of 0 (lowest level of func-
tioning) to 100 (highest level of functioning). These eight
scales were then aggregated into two summary measures:
the Physical (PCS) and Mental (MCS) Component Summary
scores, with higher scores representing better health. The scor-
ing algorithm for PCS includes positive weights for the PF,
RP, BP, GH, and VT scales and negative weights for the SF,
RE, and MH scales. The scoring algorithm for MCS includes
positive weights for the VT, SF, RE, and MH scales and neg-
ative weights for the PF, RP, BP, and GH scales. PF, RP, and
BP contributemost to the scoring of the PCS.MH, RE, and SF
scales contribute most to the scoring of the MCS. Three of the
scales (VT, GH, and SF) have noteworthy correlations with
both components. The SF-36 was constructed for self-
administration by persons 14 years of age and older and for
administration by a trained interviewer in person or by tele-
phone [23].
Other self-reported data collected included information
about participant age, gender, ethnicity, health insurance sta-
tus/type, and the educational level of the participants’ parents.
Data were also collected about bleeding disorder type (hemo-
philia A or B), whether or not the participant ever produced an
inhibitor against clotting factor treatment, and bleeding disor-
der severity. For hemophilia A and B, severity was classified
as mild, moderate, or severe corresponding to 6–50%, 1–5 %,
and <1 % factor VIII activity, respectively.
Statistical Analysis
Descriptive statistics and univariate relationships were
assessed by tabulating race (white vs non-white) by partici-
pant sociodemographic and clinical characteristics and by out-
comes of interest. Percentages were used to describe categor-
ical variables and statistical association was assessed using
Fisher’s exact test because of small sample size. Because of
the skewed nature of adherence, chronic pain, and QoL mea-
sures, medians were used to describe these outcomes when
assessed as continuous variables. Statistically significant dif-
ferences across continuous variables were assessed using the
nonparametric Wilcoxon rank sum test or Kruskal-Wallis test
(depending on degrees of freedom), as they do not assume a
normal distribution of the residuals.
Multivariable logistic regression analysis was used to predict
clotting factor treatment non-adherence (vs adherence) based
on the VERITAS cutoff described previously. To assess chronic
pain, multivariable, logistic regressionmodels were constructed
to assess factors associated with having high (vs low) levels of
chronic pain. Because QoL data were largely skewed, multivar-
iable, quantile regression models were used to assess factors
associated with SF-36 PCS and MCS subscales. For both lo-
gistic and quantile regressionmodels due to the large number of
variables collected as part of the survey and because of the
small sample size inherent in rare disease research, in addition
to the fully adjusted models, final parsimonious models were
constructed. In the final parsimonious models, we decided, a
priori, to model race (non-white vs white) as the primary vari-
able of interest and include other covariates in the model only if
they i) changed the odds ratio (OR) of the race parameter by at
least 10–15 % (i.e., confounded) [24], ii) improved the preci-
sion of the estimated race parameter, or iii) were statistically
significant at a two-tailed alpha level of .05. All statistical anal-
yses were performed using SAS 9.2 (SAS Institute Inc., Cary,
North Carolina) and STATA 12 (StataCorp LP, College Station,
Texas). All p values were calculated using two-sided tests. As
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this was an exploratory analysis, no adjustments for multiple
comparisons were made.
Results
Eighty AYAs with moderate or severe hemophilia completed
the IMPACTQoL survey. The participants were predominant-
ly male (n=79), nearly all had severe disease (91 %) and
hemophilia A (91 %). Roughly half were between the ages
of 13–17 years (51 %), and most were never married (93 %)
and had some type of health insurance (94 %). Of the 80
participating AYAs, 61 (76 %) self-reported their race as
white, 14 (18 %) were black or African-American, 2 (3 %)
were Asian, 2 (3 %) were mixed race, and 1 participant was
American Indian or Alaskan Native. Overall, 13 % (10/80) of
participants were Hispanic.
At the univariate level, compared to whites, non-whites
were more likely to have produced an inhibitor against
clotting factor treatment (74 vs 38 %, p<.01) and less likely
to have commercial health insurance (16 vs 63 %, p<.001)
(Table 1). Race had little impact on adherence (Table 2);
Table 1 Self-reported
respondent characteristics by race
among adolescents and young
adults with moderate or severe
hemophilia (n=80)
Participant characteristic Non-whitea, n (%) (n=19) White, n (%) (n=61) Fisher’s p value
Age .80
13–17 9 (47) 32 (52)
18–25 10 (53) 29 (48)
Gender .24
Male 18 (95) 61 (100)
Female 1 (5) 0 (0)
Ethnicity 1.0
Hispanic 2 (14) 8 (12)
Non-Hispanic 17 (86) 53 (88)
Health Insuranceb <.001
Medicaid or VA onlyc 12 (63) 12 (20)
Commercial only 3 (16) 32 (52)
Both 0 (0) 7 (11)
Insured—type unknown 1 (5) 8 (13)
Uninsured 3 (16) 0 (0)
Mother’s education .78
Less than bachelor’s 14 (74) 42 (69)
Bachelor’s or higher 5 (26) 19 (31)
Father’s education .16
Less than bachelor’s 16 (84) 39 (64)
Bachelor’s or higher 3 (16) 22 (36)
Bleeding disorder .19
Hemophilia A 19 (100) 54 (89)
Hemophilia B 0 (0) 7 (11)
Severity 1.0
Moderate 1 (5) 6 (10)
Severe 18 (95) 55 (90)
Inhibitor development <.01
Never 5 (26) 38 (62)
Ever 14 (74) 23 (38)
Treatment regimen .72
On-demand 3 (16) 8 (13)
Prophylaxis 16 (84) 53 (87)
aMost (73 %) non-white respondents were black or African-American, 14 % were mixed race, 9 % were Asian,
and 5 % were American Indian or Alaskan Native
b n=78, two patients answered BDon’t Know^ to whether or not they had health insurance and were not included
cOnly two patients had VA only insurance; the others had Medicaid only
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however, compared to whites, non-whites were more likely to
report high levels of chronic pain (FPS-R≥4) (63 vs 26 %,
p<.01) and had higher median chronic pain FPS-R scores (4
vs 0, p=.01) (Table 2). Acute pain FPS-R scores at the time of
having a bleed were also higher for non-white participants (6
vs 4, p=.07), though it did not reach statistical significance.
Other, non-validated pain-related measures suggested that
there were no racial differences in feeling in control of pain,
use of prescribed pain medication, or in how well health care
providers both managed and listened to participants about
their pain (Table 3). Compared to whites, QoL scores were
statistically significantly lower for non-whites for PCS, BP,
PF, RP, and SF components of the SF-36 (Table 2).
Adjusted logistic regression modeling revealed that non-
white AYAs were 5.31 (95 % CI 1.62, 17.4, p<.01) times
more likely to report high chronic pain compared to whites
(Table 4). Adjusted quantile regression modeling showed that
non-whites had median PCS scores that were 26.0 (95 % CI
11.0, 40.9, p<.01) points lower than whites when chronic pain
was excluded from the model. However, after statistical ad-
justment for chronic pain level, the difference in PCS between
whites and non-whites disappeared (Table 5), suggesting that
racial differences in chronic pain level accounted for racial
differences in physical QoL. Sensitivity analyses showed that
results were similar if race and ethnicity were treated as a
combined racial/ethnic category (non-Hispanic white vs
non-white or Hispanic), rather than two separate variables.
Discussion
Results from our study showed that, compared to white AYA
with moderate or severe hemophilia, non-whites were more
than five times as likely to experience moderate-to-severe
chronic pain (FPS-R≥4) and that worse chronic pain, in turn,
was related to worse overall physical QoL, bodily pain, phys-
ical and social functioning, and greater role limitations due to
physical health. These findings are particularly concerning
because they persisted even after statistical adjustment for
demographic (e.g., age, ethnicity, health insurance status,
and parent’s education level) and clinical factors (e.g., bleed-
ing disorder severity and type, history of inhibitor develop-
ment, and type of and adherence to recommended clotting
factor treatment regimen). Previous research, though not spe-
cific to PWH, supports our findings and has shown that
African-American children have significantly higher postop-
erative pain scores and require more morphine than white
children [25]. A systematic review of racial disparities in pain
management suggested that significant racial and ethnic dis-
parities exist in both evaluating pain and providing adequate
analgesics. Specifically, racial/ethnic minorities were more
likely to experience greater pain and worse pain management
across a variety of health care settings including acute pain
managed in the emergency department, postoperative care,
childbirth, chronic non-cancer pain, arthritis pain, cancer-
related pain, and end-of-life care [16]. Additionally, previous
research has suggested that compared to whites, black or
African-American patients with chronic pain experience
Table 2 Self-reported outcomes by race among adolescents and young
adults with moderate or severe hemophilia (n=80)
Non-whitea(n=19) White (n=61)
Outcome of interest Median Mean Median Mean p valued
Adherenceb
VERITAS-Pro 47.5 48.4 48.0 50.0 .87
VERITAS-PRN 43.0 47.3 52.0 52.4 .41
VERITAS-combined 47.0 48.3 49.0 50.3 .69
Chronic painc
FPS-R 4.0 3.9 0 1.8 .01
Acute painc
FPS-R 6.0 5.9 4.0 4.7 .07
QoL (SF-36)
PCS 59.0 63.4 83.8 78.0 .02
MCS 75.0 71.3 76.4 73.3 .62
BP 62.5 60.5 80.0 74.8 .02
PF 55.0 63.7 90.0 79.8 .03
RP 75.0 61.8 100.0 79.5 .01
GH 70.0 65.3 75.0 74.6 .21
VT 65.0 64.2 60.0 61.1 .72
SF 75.0 71.7 87.5 82.2 .05
RE 100.0 73.7 100.0 80.3 .55
MH 76.0 75.4 76.0 75.3 .96
PCS the physical composite summary score, MCS the mental composite
summary score, BP bodily pain (2 items), PF physical function (10
items), RP role limitations due to physical health problems (4 items),
GH general health (5 items), VT vitality (4 items), SF social functioning
(2 items), RE role limitations due to emotional problems (3 items), MH
emotional well-being/mental health (5 items)
aMost (73 %) non-white respondents were black or African-American,
14%weremixed race, 9%were Asian, and 5%wereAmerican Indian or
Alaskan Native
b Adherence was assessed using the Validated Hemophilia Regimen
Treatment Adherence Scale (VERITAS)-Pro for participants who report-
ed treating their bleeding disorder prophylactically (n=69). The
VERITAS-PRN was used to measure adherence for participants who re-
ported on-demand (i.e., episodic) factor treatment (n=11). Possible
VERITAS subscale scores ranged from 4 points (most adherent) to 20
(least adherent), and possible total scores ranged from 24 (most adherent)
to 120 (least adherent). As an experimental measure, we also combined
VERITAS-Pro and VERITAS-PRN responses into one category
(VERITAS-combined) to evaluate the relationship between adherence
and QoL for both prophylactic and on-demand AYA PWH simultaneously
c FPS-R is the revised Faces Pain Scale. FPS-R scores range from zero to
10 (in increments of two) with the faces representing the lowest and
highest levels of pain intensity coded as zero and 10, respectively
d p-values were calculated by comparing the difference in medians by age
group using the Wilcoxon rank sum test
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greater pain severity, more disability, and heightened psycho-
social problems related to their pain, including depression,
post-traumatic stress disorder, and anxiety [13, 26]. We have
been able to confirm many of the findings from these previous
studies in a population (AYA PWH) for whom, to our
knowledge, no data exist describing racial differences in pain
and overall QoL.
Table 3 Self-reported, non-
validated secondary pain
outcomes by race among
adolescents and young adults
with moderate or severe
hemophilia (n=80)







n (%) n (%)
Do you feel in control of your pain?
I control my pain 10 (53) 42 (69) .35
I cannot decide 7 (37) 12 (20)
My pain controls me 2 (11) 7 (11)
Do you take more pain medication (higher dosage or more pills) than prescribed?
Yes 7 (37) 11 (18) .09
No 12 (63) 50 (82)
Do you take pain medication more often (prescribed dosage but at more frequent intervals) than prescribed?
Yes 5 (26) 15 (25) 1.0
No 14 (74) 46 (75)
How often do you take your pain medication?
Every day, almost every day, or on a regular, scheduled basis 8 (42) 15 (25) .16
Only when needed 11 (58) 46 (75)
Excluding clotting factor, do you take additional pain medication when you are having a bleed?
Always, often, or sometimes 11 (58) 40 (66) .59
Never or rarely 8 (42) 21 (34)
How well do you think your doctor/provider treats/manages your pain?
Excellent or very well 13 (68) 41 (67) 1.0
Well, fair, or poor 6 (32) 20 (33)
How well do you think your doctor/provider listens to you about your pain?
Excellent or very well 15 (79) 42 (69) .56
Well, fair, or poor 4 (21) 19 (31)
aMost (73 %) non-white respondents were black or African-American, 14 % were mixed race, 9 % were Asian,
and 5 % were American Indian or Alaskan Native
Table 4 Logistic regression analyses evaluating the relationship
between race (Non-white vs white) and self-reported high (vs low)
levels of chronic pain among adolescents and young adults with
moderate or severe hemophilia (n=80)
Model OR 95 % CI p value
Crude 4.82 1.62, 14.4 <.01
Fully adjusteda 4.85 1.32, 17.8 .02
Parsimoniousb 5.31 1.62, 17.4 <.01
a In addition to non-white vs white, the fully adjusted model includes age,
ethnicity, health insurance status, mother’s education level, father’s edu-
cation level, history of inhibitor development, bleeding disorder type,
bleeding disorder severity, VERITAS-combined score, and history of
inhibitor development
b In addition to non-white vs white, the final parsimonious model includes
VERITAS-combined score and history of inhibitor development
Table 5 Quantile regression analyses evaluating the relationship
between race (Non-white vs white) and SF-36 physical composite score
(PCS) among adolescents and young adults with moderate or severe
hemophilia (n=80)
Model Coef. 95 % CI p value
Crude −24.8 −40.6, −8.92 <.01
Fully adjusted without chronic paina −26.0 −40.8, −11.1 <.01
Fully adjusted with chronic paina 0.71 −11.0, 9.56 .89
Parsimonious without chronic painb −26.0 −40.9, −11.0 <.01
Parsimonious with chronic painb 2.38 −13.9, 9.2 .68
a In addition to non-white vs white, the fully adjusted model includes age,
ethnicity, health insurance status, mother’s education level, father’s edu-
cation level, history of inhibitor development, bleeding disorder type,
bleeding disorder severity, VERITAS-combined score, and history of
inhibitor development
b In addition to non-white vs white, the final parsimonious model includes
age, ethnicity, and history of inhibitor development
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Racial differences in pain and QoL discovered in our study,
and in previous research, could partially be driven by biologic
and genetic differences. It has long been identified that genetic
factors may play a role in the perception and response to pain
[27]. It has been previously suggested that genetic differences
could influence activity in the higher nervous centers that
modulate pain through the activation of the descending and
neural inhibitory controls of African-Americans [28], which
could contribute to enhanced pain sensitivity to noxious stim-
uli [8]. Others have postulated that differences in pain could be
due in part to potential differences in circulating B-endorphins
in response to stress among differing racial groups [29].More-
over, significant variations in the allele frequency for multiple
gene loci among racial groups have been identified that mod-
ulate nociceptive transduction, opioid analgesic effects, and
neurotransmitter metabolism [16]. Other research has sug-
gested that endogenous pain regulatory mechanisms in
African-Americans may contribute to greater rates of clinical
pain symptoms [30, 31]. Finally, consistent with previous re-
search [32–38], our results showed that non-white AYA PWH
were much more likely to have ever produced an inhibitor
against clotting factor treatment. Though reasons for this are
unknown, one possibility may be that a greater degree of
population-level variation exists in factor VIII amino acid se-
quence among non-white persons, leading to an increased
probability of a mismatch with replacement factor proteins
[39, 40]. Other studies, however, have suggested that varia-
tions in factor VIII genes do not explain higher inhibitor fre-
quencies in African-American and Hispanic patients [41] and
that genetic factors other than the disease-causing mutation
could play a role [34, 42, 43]. Another report suggested that
patients receiving plasma-derived activated prothrombin com-
plex concentrates were more likely to be African-American
[44], which may suggest that our inhibitor (ever vs never)
designation may not fully control for the impact of inhibitor
development.
Secondly, social and cultural factors may drive racial dif-
ferences. It has been previously suggested that differences in
provider cultural beliefs and stereotypes regarding pain in mi-
nority individuals affects the prescribing of opioid analgesia
[45–48] and may even indirectly influence provider decision-
making and the overall content and tone of the clinical en-
counter [49–52]. It is important to note, however, that we
did not find any significant differences (all p>.55) across ra-
cial groups in how well participants thought their health care
provider treated and managed their pain or in how their health
care provider listened to them about their pain—though vali-
dated measures were not used to address those specific aspects
of provider pain management in our survey. In addition to
potential conscious and unconscious health care provider bias
against racial minorities, there is also the possibility that racial
minorities have heightened sensitivity to being labeled as
complainers or are afraid that pain means a progression of
illness, and thus may underreport pain to their health care
providers [53].
Language and/or health literacy barriers may exist among
certain racial/ethnic groups, limiting appropriate assessment
and treatment of pain by medical providers. This may lead
to an underestimation of pain severity in minority patients,
which, in turn, may result in minority populations being less
likely to receive appropriate pain management [45]. Further-
more, the degree of cultural affiliation and acculturation may
also have a relationship to the pain response among varying
racial/ethnic groups [8]. Pain responses may also differ based
upon the culturally appropriate strategies utilized for reducing
pain. Designing culturally appropriate treatment strategies
should include personally delivered interventions that take
into account cultural practices, philosophies, products, and/
or appropriate environment vehicles to facilitate behavior
change [16].
A third potential explanation for racial differences in chron-
ic pain revolves around psychological issues—primarily be-
liefs and coping strategies. Previous research suggests that
African-Americans use emotion-focused coping strategies
more than whites [53]. Minority patients have been reported
to display stoicism, describe pain as Binevitable,^ have a fear
of addiction to pain medications, and express concerns of
intolerable side effects [54]. Generally speaking, minority pa-
tients rely more on alternative and complementary pain treat-
ments [16] and are more likely to use prayer and other reli-
gious coping strategies [15, 16, 18, 28], perhaps due to a
mistrust in the medical community and inadequate medical
treatment for pain relief [28]. Indeed, there may be systematic
differences in psychological distress and pain-coping strate-
gies across racial groups [55].
Final factors that may affect the disparity in pain treatment
amongminorities include health care system-related variables.
It is well known that racial/ethnic minorities and the poor have
decreased access to health care [16] which translates to more
limited access to pain treatment [56]. Even if minority patients
receive a prescription for pain medication, they may face ad-
ditional structural barriers such as limited availability of opi-
oids in their neighborhood pharmacy, lack of adequate health
insurance to pay for their prescription, or financial difficulties
in paying for health care despite having health insurance [57].
In this study, however, race/ethnicity had little impact on ad-
herence to prescribed clotting factor treatment regimen.
This study has limitations. Primarily, data were cross-
sectional; thus, causal inference cannot be made. Temporality,
however, is not problematic when assessing the effect of
race/ethnicity on health outcomes. A second limitation is that
all data are self-reported. As such, information about blood
disorder type and severity, health insurance coverage, and
other demographic, clinical, and behavioral information are
not confirmed by medical record review or administrative
claims data. However, by obtaining data through self-report,
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this study was able to collect important, reliable, and valid
patient-reported outcome data about adherence and chronic
pain. Patient-reported data about racial categories and pain
are considered the Bgold standard,^ and the VERITAS scales
are the only validated measures of adherence to clotting factor
treatment developed to date—though we did combine them
into one experimental measure for modeling purposes. Anoth-
er limitation is that we were only able to dichotomize race as
white vs non-white, as we did not have sufficient sample size
to evaluate differences in racial disparities depending on spe-
cific, individual racial groups. Sensitivity analyses, however,
suggested that ethnic disparities may exist in addition to racial
disparities, as results were similar whether or not Hispanic
whites were included in the Bwhite only^ category or not.
Future studies should try to examine differences across indi-
vidual racial/ethnic groups with sufficient statistical power. In
addition, because of the way we evaluated inhibitor develop-
ment (ever vs never), there may be residual confounding with
respect to racial differences in inhibitor development, inhibitor
type (transient vs persistent), bleeding patterns, and/or target
joint development which was not captured in our study and
should be examined in future research. Finally, AYA PWH
were primarily recruited from large national or regional hemo-
philia meetings. Thus, our convenience sample of AYA PWH
may not adequately represent the broader AYA PWH popula-
tion who do not typically attend these meetings.
Conclusion
Results showed that non-white AYA patients with moderate or
severe hemophilia were more than five times as likely as
whites to report high levels of chronic pain and that worse
chronic pain, in turn, led to non-whites having worse overall
physical QoL, bodily pain, physical and social functioning,
and greater role limitations due to physical health. These find-
ings are particularly concerning because they persisted even
after statistical adjustment for demographic and clinical fac-
tors. Intrinsically, self-reported racial classifications are not
particularly meaningful and are largely arbitrarily and socially
constructed. Future research should more thoroughly examine
the complex interplay between biological and genetic, social
and cultural (including bias and discrimination), psychologi-
cal and emotional, and health care system-related factors that
could all contribute to these racial/ethnic disparities in chronic
pain management and QoL. These factors, either alone or in
combination, are the building blocks for the construction of
racial/ethnic disparities and also represent the foundation for
which programs addressing disparate health outcomes for
racial/ethnic groups should be built. AYAs will remain an
especially important target for this research, given that previ-
ous studies have shown that, regardless of race or ethnicity,
compared to older adults, AYAs are less likely to have high
pain thresholds, develop effective pain-coping skills, and ad-
equately manage their pain [18].
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